Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))
• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))
• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Various reasons (death, severe mucositis, noncompliance, etc.))
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Voluntary withdrawal)
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Voluntary withdrawal)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Voluntary withdrawal)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Voluntary withdrawal)
• Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms  + (Withdrawing from the study because of difficulty in adhering to the four times daily oral care regimen)
• Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis  + (Withdrawn (changed mind before study))
• Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis  + (Withdrawn (intercurrent disease))
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (Withdrew consent (n=1); hospital switch (n=1); postponed surgery (n=1))
• Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial  + (Withdrew due to scheduling conflicts (n=6); not separated by arm: no longer wishing to comply with dietary requirements (n=3); cancer recurrence (n=3); death (n=2))
• Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial  + (Withdrew due to scheduling conflicts (n=6); not separated by arm: no longer wishing to comply with dietary requirements (n=3); cancer recurrence (n=3); death (n=2))
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (Withdrew during intervention)
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (Withdrew during intervention)
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (Withdrew during intervention)
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (Withdrew during intervention)

• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (Withdrew for personal reasons n=15 Adverse Events n=5)

• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (Withdrew for personal reasons n=18 Adverse Events n=5)
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (Withdrew for reasons other than study agent related adverse events)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (lost to follow-up)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (lost to follow-up)
• Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...)  + (n = 4 did not received treatment - transferred care: 1 - myocardial infarction prior to chemotherapy: 1 - became eligible for cisplatin: 2)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (n=1 died during the course of radiation, n=1 denied radiation therapy, n=1 left the study due to personal reason)
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (n=1 elevated serum testosterone at baseline, n=1 use of digoxin discovered before treatment began (one), n=1 received treatment and discovered to have an elevated baseline serum testosterone level, n=4 withdrawn before first post-baseline imaging studies)
• Urashima et al. (2019): Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers The AMATERASU Randomized Clinical Trial  + (n=1 lost to follow-up within 6 month, n=23 stopped study medication (n=14 for nonmedical reasons, n=9 for medical reasons))
• Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer  + (n=11 chemotherapy was not indicated, n=3 refused chemotherapy)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (n=2 non-compliance)
• Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia  + (n=2 not start treatment (withdrew consent); n=3 not complete 12 weeks (n=2 withdrew consent, n=1 non-compliant))
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (n=2 protocol violations, n=7 withdrew for reasons other than study agent related adverse events)
• Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia  + (n=4 not start treatment (n=3 withdrew consent, n=1 ineligible); n=1 not complete 12 weeks, found ineligible)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (n=4, death before day 30)
• Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer  + (n=9 chemotherapy was not indicated, n=1 refused chemotherapy)
• Urashima et al. (2019): Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers The AMATERASU Randomized Clinical Trial  + (stopped study medication (n=10 for nonmedical reasons, n=9 for medical reasons))